首页> 外文期刊>Biomedicine & pharmacotherapy =: Biomedecine & pharmacotherapie >TMT-based proteomics analysis of the anti-hepatocellular carcinoma effect of combined dihydroartemisinin and sorafenib
【24h】

TMT-based proteomics analysis of the anti-hepatocellular carcinoma effect of combined dihydroartemisinin and sorafenib

机译:基于TMT的蛋白质组学分析抗肝细胞癌蛋白酶蛋白和索拉昔替

获取原文
获取原文并翻译 | 示例
           

摘要

Hepatocellular carcinoma (HCC), as the major primary liver cancer, is one of the most prevalent malignant diseases with a high mortality rate worldwide. Prior studies have demonstrated that dihydroartemisinin (DHA), the semisynthetic derivative of artemisinin, possesses anti-HCC activity. The multikinase inhibitor sorafenib has been approved for the treatment of HCC. However, the anti-HCC efficacy of DHA combined with sorafenib has not been reported. In this study, we confirmed the significantly enhanced anti-HCC efficacy of DHA in combination with sorafenib compared with that of each agent alone. Tandem Mass Tag (TMT) peptide labeling coupled with LC-MS/MS was used to quantify the proteins from the control, DHA, sorafenib, and DHA + sorafenib groups. In total, 532, 426, 628 differentially expressed proteins (fold change >1.20 or <0.83 and P-value <0.05) were determined by comparing DHA versus control, sorafenib versus control and DHA + sorafenib versus control groups, respectively. Moreover, optimized screening was performed, and 101 optimized differentially expressed proteins were identified. The results of functional analysis of the optimized differentially expressed proteins suggested that they were enriched in cell components such as membrane-bound vesicles, extracellular vesicles, and organelle lumens, and they were mainly involved in biological processes such as cellular component organization, response to stress, and response to chemicals; in addition, they were related to various molecular functions such as protein binding, chromatin binding and enzyme binding. KEGG pathway analysis showed that the optimized differentially expressed proteins were enriched in pyrimidine metabolism, RNA polymerase, base excision repair, and osteoclast differentiation. Protein-protein interaction (PPI) networks of some of the optimized upregulated proteins suggested that they might not only affect vitamin and fat digestion and absorption but may also be involved in tight junctions. In the PPI network, some of the optimized downregulated proteins were enriched in base excision repair, RNA polymerase, purine metabolism, pyrimidine metabolism and mucin type O-glycan biosynthesis. Overall, this research explored the anti-HCC efficacy of DHA combined with sorafenib by using the TMT-based quantitative proteomics technique and might facilitate the understanding of the related anti-HCC molecular mechanism.
机译:作为主要原发性肝癌的肝细胞癌(HCC)是全球死亡率高的最普遍的恶性疾病之一。事先研究表明,氨基氨基蛋白(DHA)是氨化素的半合成衍生物,具有抗HCC活性。多酮酶抑制剂索拉非尼被批准用于治疗HCC。然而,DHA与索拉非尼结合的抗HCC效力尚未报告。在这项研究中,我们确认DHA与单独的每种试剂相结合的DHA的抗HCC抗HCC效力。与LC-MS / MS偶联的串联质量标签(TMT)肽标记用于量化来自对照,DHA,Sorafenib和DHA + Sorafenib组的蛋白质。通过比较DHA与对照,索拉非尼与对照和DHA + Sorafenib与对照组,确定总,532,426,628差异表达蛋白(折叠变化> 1.20或<0.83和p值<0.05)。此外,进行了优化的筛选,并鉴定了101种优化的差异表达蛋白质。优化的差异表达蛋白的功能分析结果表明它们富含细胞成分,例如膜结合的囊泡,细胞外囊泡和细胞器流明,它们主要参与细胞组织组织如细胞组织,反应应激和对化学品的反应;此外,它们与蛋白质结合,染色质结合和酶结合等各种分子功能有关。 Kegg途径分析表明,优化的差异表达蛋白质富含嘧啶代谢,RNA聚合酶,基础切除修复和骨壳分化。一些优化的上调蛋白质的蛋白质 - 蛋白质相互作用(PPI)网络表明它们不仅可能影响维生素和脂肪消化和吸收,而且也可能参与紧密的连接点。在PPI网络中,一些优化的下调蛋白质富含基础切除修复,RNA聚合酶,嘌呤代谢,嘧啶代谢和粘膜型O-聚糖生物合成。总体而言,本研究探讨了DHA通过使用TMT的定量蛋白质组学技术联合索拉非尼的抗HCC疗效,并且可以促进对相关抗HCC分子机制的理解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号